Coherus BioSciences, Inc.
Index- P/E- EPS (ttm)-3.76 Insider Own2.03% Shs Outstand77.96M Perf Week8.98%
Market Cap503.34M Forward P/E8.97 EPS next Y0.72 Insider Trans0.00% Shs Float71.61M Perf Month-4.60%
Income-291.80M PEG- EPS next Q-0.63 Inst Own- Short Float / Ratio16.83% / 10.50 Perf Quarter3.38%
Sales211.00M P/S2.39 EPS this Y1.20% Inst Trans-1.54% Short Interest12.05M Perf Half Y-34.52%
Book/sh-1.76 P/B- EPS next Y146.80% ROA-53.80% Target Price17.12 Perf Year-49.61%
Cash/sh2.45 P/C2.63 EPS next 5Y- ROE477.10% 52W Range5.58 - 14.11 Perf YTD-18.81%
Dividend- P/FCF- EPS past 5Y3.50% ROI-78.20% 52W High-54.43% Beta0.96
Dividend %- Quick Ratio2.50 Sales past 5Y167.00% Gross Margin66.80% 52W Low15.22% ATR0.40
Employees359 Current Ratio2.70 Sales Q/Q-38.10% Oper. Margin- RSI (14)46.30 Volatility3.85% 6.92%
OptionableYes Debt/Eq- EPS Q/Q-26.90% Profit Margin- Rel Volume0.99 Prev Close6.48
ShortableYes LT Debt/Eq- EarningsMar 06 AMC Payout- Avg Volume1.15M Price6.43
Recom2.40 SMA200.67% SMA50-13.06% SMA200-23.84% Volume1,156,272 Change-0.77%
Mar-28-23Upgrade UBS Neutral → Buy $11
Jun-14-22Initiated UBS Neutral $7
Mar-07-22Downgrade JP Morgan Overweight → Neutral $15
Jul-16-20Initiated BofA Securities Neutral $20
Apr-17-20Initiated SunTrust Buy $26
Aug-13-19Initiated Mizuho Buy
Aug-02-19Reiterated Maxim Group Buy $25 → $27
Aug-02-19Reiterated H.C. Wainwright Buy $28 → $29
Jun-11-19Initiated Barclays Overweight $30
May-07-19Initiated H.C. Wainwright Buy $28
Show Previous Ratings
Mar-29-23 03:30AM
Mar-27-23 11:38AM
Mar-08-23 06:59AM
Mar-07-23 11:32AM
Mar-06-23 05:15PM
04:01PM Loading…
Mar-01-23 08:25AM
Feb-28-23 08:25AM
Feb-15-23 08:25AM
Feb-13-23 08:25AM
Feb-03-23 05:30PM
Jan-30-23 05:57PM
Jan-09-23 08:20AM
Jan-04-23 07:01AM
07:12AM Loading…
Jan-03-23 07:12AM
Dec-25-22 08:16AM
Dec-24-22 12:01AM
Dec-21-22 06:52AM
Nov-10-22 06:18AM
Nov-08-22 05:25PM
Nov-01-22 07:30AM
Oct-18-22 10:48AM
Oct-12-22 07:30AM
Oct-10-22 11:49AM
Sep-19-22 07:30AM
Sep-12-22 08:30AM
Sep-02-22 09:55AM
Aug-29-22 08:49PM
09:55AM Loading…
Aug-19-22 09:55AM
Aug-06-22 05:00AM
Aug-04-22 05:25PM
Aug-03-22 09:55AM
Aug-02-22 07:15PM
Aug-01-22 11:15PM
Jul-28-22 04:01PM
Jul-18-22 10:59AM
Jul-06-22 08:00AM
Jun-27-22 08:34AM
Jun-22-22 04:30PM
May-11-22 06:00PM
May-10-22 08:45AM
May-07-22 01:30AM
May-05-22 05:35PM
May-03-22 09:45PM
May-02-22 04:09PM
Apr-29-22 04:01PM
Apr-28-22 03:02PM
Apr-20-22 02:25PM
Apr-14-22 08:30AM
Apr-08-22 01:10PM
Apr-05-22 04:30PM
Mar-29-22 09:15AM
Mar-22-22 04:30PM
Mar-15-22 08:00AM
Mar-04-22 04:05PM
Feb-18-22 12:00AM
Feb-17-22 05:15PM
Feb-15-22 04:30PM
Feb-14-22 08:30AM
Feb-11-22 08:30AM
Feb-07-22 05:25PM
Jan-10-22 07:30AM
Jan-07-22 08:30AM
Jan-04-22 08:32AM
Dec-20-21 07:59AM
Dec-17-21 09:09AM
Dec-16-21 04:30PM
Dec-15-21 09:08PM
Dec-13-21 07:00AM
Nov-18-21 06:45PM
Nov-16-21 09:08AM
Nov-15-21 08:30AM
Nov-11-21 05:46AM
Nov-10-21 04:15PM
Nov-08-21 10:00PM
Nov-05-21 08:30AM
Nov-01-21 07:30AM
Oct-29-21 04:12PM
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.